OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
KMCS56

KMC Speciality Hospitals (India) Ltd

Healthcare Facilities & ServicesVerified

KMC Speciality Hospitals maintains a debt-to-equity ratio of 0.57, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is assessed as medium, with a current ratio of 0.72, suggesting that it may face challenges in meeting short-term obligations without additional cash inflows. The return on equity (ROE) of 4.94% and return on assets (ROA) of 2.69% are below the typical thresholds for high-performing healthcare providers, indicating that the company is not generating strong returns relative to its equity and asset base. Profitability metrics show that the company's net income of INR 70.86 million is derived from a gross profit of INR 385.38 million, with an operating income of INR 91.38 million. These figures suggest that the company is managing to maintain positive operating margins, but the net income margin is relatively low, which could be a concern for investors seeking higher returns. The company's operating cash flow of INR 384.20 million is a positive sign, indicating that it is generating sufficient cash from operations to support its activities. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This lack of diversification could expose the company to higher risks if there are any adverse changes in the local market or regulatory environment. The company's capital expenditure of INR -752.72 million indicates a significant outflow of cash, which may be related to the expansion or maintenance of its hospital facilities. Looking ahead, the company's growth trajectory is expected to be modest, with no significant revenue growth projected in the next fiscal year. The company's capital expenditure is expected to remain high, which could impact its cash flow and profitability in the short term. The company's risk assessment indicates a medium liquidity risk, primarily due to its current ratio being below 1, and a low dilution risk, as there are no immediate plans for share issuance or dilution. Recent events, including the company's financial filings and transcripts, have not indicated any major changes in the company's strategic direction or operational performance. The company continues to focus on maintaining its hospital services and improving its financial metrics. The company's risk assessment also highlights the need for continued monitoring of its liquidity position and capital expenditure to ensure long-term sustainability.

30-day price · KMCS+16.23 (+20.6%)
Low$78.00High$97.60Close$94.98As of14 May, 00:00 UTC
Profile
CompanyKMC Speciality Hospitals (India) Ltd
TickerKMCS.BO
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. KMC Speciality Hospitals (India) Ltd operates in the healthcare facilities and services sector, providing specialized hospital services and generating revenue primarily through patient care and related medical services.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a high confidence level of 0.92 based on verified market data.

KMC Speciality Hospitals maintains a debt-to-equity ratio of 0.57, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is assessed as medium, with a current ratio of 0.72, suggesting that it may face challenges in meeting short-term obligations without additional cash inflows. The return on equity (ROE) of 4.94% and return on assets (ROA) of 2.69% are below the typical thresholds for high-performing healthcare providers, indicating that the company is not generating strong returns relative to its equity and asset base. Profitability metrics show that the company's net income of INR 70.86 million is derived from a gross profit of INR 385.38 million, with an operating income of INR 91.38 million. These figures suggest that the company is managing to maintain positive operating margins, but the net income margin is relatively low, which could be a concern for investors seeking higher returns. The company's operating cash flow of INR 384.20 million is a positive sign, indicating that it is generating sufficient cash from operations to support its activities. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This lack of diversification could expose the company to higher risks if there are any adverse changes in the local market or regulatory environment. The company's capital expenditure of INR -752.72 million indicates a significant outflow of cash, which may be related to the expansion or maintenance of its hospital facilities. Looking ahead, the company's growth trajectory is expected to be modest, with no significant revenue growth projected in the next fiscal year. The company's capital expenditure is expected to remain high, which could impact its cash flow and profitability in the short term. The company's risk assessment indicates a medium liquidity risk, primarily due to its current ratio being below 1, and a low dilution risk, as there are no immediate plans for share issuance or dilution. Recent events, including the company's financial filings and transcripts, have not indicated any major changes in the company's strategic direction or operational performance. The company continues to focus on maintaining its hospital services and improving its financial metrics. The company's risk assessment also highlights the need for continued monitoring of its liquidity position and capital expenditure to ensure long-term sustainability.
Key takeaways
  • KMC Speciality Hospitals has a moderate debt-to-equity ratio of 0.57, indicating a balanced capital structure.
  • The company's ROE of 4.94% and ROA of 2.69% are below industry benchmarks, suggesting suboptimal returns.
  • The company's liquidity position is medium, with a current ratio of 0.72, indicating potential short-term liquidity challenges.
  • The company's revenue is concentrated in a single business segment, increasing its exposure to market and regulatory risks.
  • The company's capital expenditure is expected to remain high, which could impact its cash flow and profitability in the short term.
  • The company's risk assessment indicates a low dilution risk and a need for continued monitoring of its liquidity position.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$449.1M
Gross profit$385.4M
Operating income$91.4M
Net income$70.9M
R&D
SG&A
D&A
SBC
Operating cash flow$384.2M
CapEx-$752.7M
Free cash flow
Total assets$2.64B
Total liabilities$1.20B
Total equity$1.44B
Cash & equivalents$178.3M
Long-term debt$818.2M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$1.03B$172.0M$127.8M-$219.1M
FY-3$1.36B$307.8M$237.3M$167.8M
FY-2$1.56B$338.0M$266.9M-$97.8M
FY-1$1.77B$383.7M$303.8M-$356.7M
FY0$2.32B$381.4M$214.3M-$235.0M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$1.05B$633.3M
FY-3$1.29B$868.0M
FY-2$1.82B$1.14B
FY-1$2.64B$1.44B$21.3M
FY0$2.86B$1.64B$58.2M
PeriodOCFCapExFCFSBC
FY-4$256.0M-$408.5M-$219.1M
FY-3$291.2M-$134.8M$167.8M
FY-2$323.3M-$441.1M-$97.8M
FY-1$384.2M-$752.7M-$356.7M
FY0$575.8M-$638.8M-$235.0M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$449.1M$91.4M$70.9M
FQ-6$530.7M$88.6M$55.1M
FQ-5$562.3M$75.7M$38.8M
FQ-4$613.6M$111.6M$75.1M
FQ-3$609.3M$103.4M$45.2M
FQ-2$665.5M$113.7M$75.4M
FQ-1$749.0M$155.4M$108.4M
FQ0$820.6M$194.2M$137.3M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$2.64B$1.44B$178.3M
FQ-6
FQ-5$2.84B$1.53B$41.0M
FQ-4
FQ-3$2.86B$1.64B$1.5M
FQ-2
FQ-1$3.00B$1.82B$58.8M
FQ0
PeriodOCFCapExFCFSBC
FQ-7$384.2M-$752.7M
FQ-6
FQ-5$236.7M-$443.0M
FQ-4
FQ-3$575.8M-$638.8M
FQ-2
FQ-1$306.8M-$56.3M
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$1.44B
Net cash-$639.8M
Current ratio0.7
Debt/Equity0.6
ROA2.7%
ROE4.9%
Cash conversion5.4%
CapEx/Revenue-1.7%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricKMCSActivity
Op margin20.3%7.7% medp25 -2.4% · p75 15.5%top quartile
Net margin15.8%5.9% medp25 -3.8% · p75 12.8%top quartile
Gross margin85.8%45.5% medp25 31.1% · p75 62.9%top quartile
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-167.6%-7.0% medp25 -14.9% · p75 -3.2%bottom quartile
Debt / equity57.0%25.0% medp25 3.8% · p75 63.3%above median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-14 00:04 UTC#d1005009
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 08:22 UTCJob: 5b417014